Showing 2611-2620 of 7016 results for "".
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.APP Biosimilar Education Video Series Module 1
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/app-biosimilar-education-video-series-module-1/15966/This series is designed to give advanced practice providers a better understanding of biosimilars as treatment options and how to discuss these options with patients. In this four-module series, APPs will learn how to introduce biosimilars to their patients, discuss initiation of a biologic/biosiNeoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
https://reachmd.com/programs/project-oncology/neoadjuvant-nivolumab-with-or-without-ipilimumab-in-resectable-cscc/54700/Using fMRI to Identify Early Alzheimer’s Disease Subgroups
https://reachmd.com/programs/neurofrontiers/fmri-early-alzheimers-subgroups/40003/Preclinical Alzheimer’s disease presents a unique challenge due to its silent progression and biological complexity. However, emerging data highlights the role of brain connectivity in distinguishing patient subtypes before clinical symptoms arise. Join Dr. Hamid Abuwarda as he discusses how functioRefining First-Line Therapy in Advanced Endometrial Care: LEAP-001 Trial Results
https://reachmd.com/programs/project-oncology/refining-first-line-therapy-in-advanced-endometrial-care-leap-001-trial-results/35507/To explore a potential alternative to chemotherapy, the ENGOT-en9/LEAP-001 trial compared lenvatinib/pembrolizumab to standard chemotherapy in patients with advanced or recurrent endometrial cancer. Learn how these results may shape biomarker-driven approaches and patient selection in frontline endoProstate Cancer and Cannabis Use: Exploring Results From a Case-Control Study
https://reachmd.com/programs/clinicians-roundtable/prostate-cancer-and-cannabis-use-exploring-results-from-a-case-control-study/35696/Preclinical findings in animal models have shown that activating cannibinoid receptors can shrink prostate tumors in animal models. To explore whether these effects translate to human populations, a recent study examined a potential link between cannabis use and the development of prostate cancer. HAging and Multiple Sclerosis: Insights from the 2024 CMSC Consensus Statement
https://reachmd.com/programs/frontlines-multiple-sclerosis/aging-and-multiple-sclerosis-insights-from-the-2024-cmsc-consensus-statement/32664/Tune in to hear two experts share their insights and takeaways from the Consortium of Multiple Sclerosis Centers’ 2024 Consensus Statement on MS and aging.Using CGMs and Insulin Pumps to Treat Pediatric Patients with T1D
https://reachmd.com/programs/diabetes-discourse/using-cgms-and-insulin-pumps-to-treat-pediatric-patients-with-t1d/16366/Tune in to learn more about some of the latest technologies used to treat pediatric patients with type 1 diabetes.Insights into Inhaled Asthma Therapies: Uncovering Updates from NAEPP and GINA
https://reachmd.com/programs/deep-breaths-updates-chest/insights-into-inhaled-asthma-therapies-uncovering-updates-from-naepp-and-gina/16119/Tune in to hear experts discuss inhaled therapies and key updates from NAEPP and GINA 2023 on asthma treatment.How to Reduce Harm for Patients in Family Planning Clinics Who Use Substances
https://reachmd.com/programs/advances-in-womens-health/how-to-reduce-harm-for-patients-in-family-planning-clinics-who-use-substances/16167/Explore strategies for reducing harm among substance-using pregnant patients with this recap of a session featured at the 2023 SFP Annual Meeting.